Mortality Rates for Breakthrough Invasive Fungal Infections in a Multicenter Trial of Posaconazole vs Standard Azole Prophylaxis

D.J. Winston*, O.A. Comely, J. Maertens, J. Perfect, D.D. Helfsott, A.J. Ullmann, J. Ho[owiecki, D. Stocke[bers, Y-T. Goh, M. Petrini, T.J. Wa[sh, C. Hardalo, D. Ansulo- Gonzalez.

Author address: 

University of California, Los Angeles Medical Center, Los Angeles, CA, USA


Background: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing induction chemotherapy are at high risk for invasive fungal infections (IFIs). In a mu[ticenter, randomized study of AML/MDS patients, posaconazo[ e (POS) prophylaxis prevented significantly more breakthrough IFIs than standard azo[e (fluconazo[ e [FLU] or itraconazo[e [ITZ]) prophylaxis. Objectives: We evaluated mortality rates and causes of death in patients from this study who developed a breakthrough IFI during POS or standard azo[e prophylaxis. Methods: Patients with AML or MDS and chemotherapy- induced neutropenia (~

abstract No: 


Full conference title: 

14th International Symposium of Infections in the Immunocompromised Host
    • ISIIH, 14th